Abstract
BackgroundInvasive micropapillary carcinoma (IMPC) of the breast is a rare variant of invasive ductal carcinoma (IDC). The prognosis of IMPC compared with that of IDC remains controversial; we conducted a meta-analysis to evaluate the prognostic difference between IMPC and IDC.MethodsWe searched the PubMed, Cochrane Library, and EMBASE databases for relevant studies comparing overall survival (OS), disease-specific survival (DSS), relapse-free survival (RFS), local-regional recurrence-free survival (LRRFS) or distant metastasis-free survival (DMFS) rates between IMPC and IDC. Fixed-effect and random-effect models were utilized based on the heterogeneity of the eligible studies. Heterogeneity was further evaluated by subgroup and sensitivity analyses.ResultsFourteen studies with 1888 IMPC patients were included in the meta-analysis. The summarized odds ratio (OR) and 95% confidence interval (95% CI) was calculated to estimate the prognostic difference between IMPC and IDC. IMPC patients showed an unfavorable prognosis for RFS (OR; 2.04; 95% CI: 1.63–2.55) and LRRFS (OR: 2.82; 95% CI: 1.90–4.17) compared with IDC. However, no significant difference was observed in OS (OR: 0.93; 95% CI: 0.78–1.10), DSS (OR: 1.16; 95% CI: 0.95–1.40) and DMFS (OR: 0.95; 95% CI: 0.67–1.35) between IMPC and IDC. No obvious statistical heterogeneity was detected, except for DSS. Funnel plots and Egger’s tests did not reveal publication bias, except for RFS.ConclusionsThis analysis showed that IMPC patients have a higher rate of loco-regional recurrence than IDC patients. However, OS, DSS and DMFS were not significantly different between IMPC and IDC. These results could help clinicians select therapeutic and follow-up strategies for IMPC patients.
Highlights
Invasive micropapillary carcinoma (IMPC) of the breast is a rare variant of invasive ductal carcinoma (IDC)
Inclusion and exclusion criteria The articles were included in the present analysis if they met the following criteria: (I) studies involved must compare the prognostic outcomes between IMPC and IDC; (II) detailed statistics should report outcomes, such as percentages of overall survival (OS), disease-specific survival (DSS), relapse-free survival (RFS), local-regional recurrence-free survival (LRRFS) or distant metastasis-free survival (DMFS); and (III) if the studied population was duplicated, only the previous publication or the publication with the largest sample size would be included
The present study is the first meta-analysis to explore the prognostic differences between IMPC and IDC
Summary
Invasive micropapillary carcinoma (IMPC) of the breast is a rare variant of invasive ductal carcinoma (IDC). Different breast cancer subtypes show various prognoses, since. The most common histological type is invasive carcinoma of no special type, known as invasive ductal carcinoma (IDC), which accounts for approximately 75% of all invasive breast cancers [5]. Invasive micropapillary carcinoma (IMPC) was listed as a rare subtype of invasive breast. Invasive micropapillary carcinoma (IMPC) was first described in breast cancer as having an “exfoliative appearance” by Fisher et al [13] in 1980, and first proposed as the term of “invasive micropapillary carcinoma” by Siriaunkgul et al [14] in 1993. The microscopic evaluation of histological differences is vital to clinical diagnosis
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
